Cargando…
Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study
Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given pru...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172323/ https://www.ncbi.nlm.nih.gov/pubmed/34122678 http://dx.doi.org/10.1155/2021/6620585 |
_version_ | 1783702520831410176 |
---|---|
author | Gourgoulianis, Konstantinos Ruggieri, Alessandro del Vecchio, Alessandra Calisti, Fabrizio Comandini, Alessandro Esposito, Giovanna Di Loreto, Giorgio Tzanakis, Nikolaos |
author_facet | Gourgoulianis, Konstantinos Ruggieri, Alessandro del Vecchio, Alessandra Calisti, Fabrizio Comandini, Alessandro Esposito, Giovanna Di Loreto, Giorgio Tzanakis, Nikolaos |
author_sort | Gourgoulianis, Konstantinos |
collection | PubMed |
description | Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients >40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7–10 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I/II: 94.8%; chronic bronchitis duration >10 years: 24.9%) were consecutively enrolled. At baseline, >80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile. |
format | Online Article Text |
id | pubmed-8172323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-81723232021-06-11 Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study Gourgoulianis, Konstantinos Ruggieri, Alessandro del Vecchio, Alessandra Calisti, Fabrizio Comandini, Alessandro Esposito, Giovanna Di Loreto, Giorgio Tzanakis, Nikolaos Can Respir J Research Article Real-world evidence regarding the effectiveness of prulifloxacin in the treatment of acute exacerbations of chronic bronchitis (AECB) is limited. Therefore, this study aimed to assess the rates and time to symptom improvement and resolution in patients with moderate-to-severe AECB who were given prulifloxacin in the routine care in Greece. This observational, prospective study, conducted in 15 hospital-based clinics across Greece, enrolled outpatients >40 years old, with moderate-to-severe AECB, for whom the physician had decided to initiate treatment with prulifloxacin. Data were collected at prulifloxacin onset (baseline), 7–10 days after baseline, and at least 28 days after therapy completion. Between 23 November 2015 and 27 January 2018, 305 patients (males: 76.4%; mean (standard deviation) (SD) age: 69.7 (9.8) years; Anthonisen type I/II: 94.8%; chronic bronchitis duration >10 years: 24.9%) were consecutively enrolled. At baseline, >80% had increased sputum volume, cough, dyspnoea, and sputum purulence. Prulifloxacin improved symptoms in 99.7% of the patients after a mean (SD) of 5.47 (3.57) days, while symptoms fully recovered after a mean (SD) of 10.22 (5.00) days in 95.4%. The rate of adverse events related to prulifloxacin was 1.3% (serious: 0.7%). In the routine care in Greece, prulifloxacin was highly effective in moderate-to-severe AECB, while displaying a predictable safety profile. Hindawi 2021-05-25 /pmc/articles/PMC8172323/ /pubmed/34122678 http://dx.doi.org/10.1155/2021/6620585 Text en Copyright © 2021 Konstantinos Gourgoulianis et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Gourgoulianis, Konstantinos Ruggieri, Alessandro del Vecchio, Alessandra Calisti, Fabrizio Comandini, Alessandro Esposito, Giovanna Di Loreto, Giorgio Tzanakis, Nikolaos Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
title | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
title_full | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
title_fullStr | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
title_full_unstemmed | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
title_short | Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice—The “AIOLOS” Study |
title_sort | prulifloxacin effectiveness in moderate-to-severe acute exacerbations of chronic bronchitis: α noninterventional, multicentre, prospective study in real-life clinical practice—the “aiolos” study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172323/ https://www.ncbi.nlm.nih.gov/pubmed/34122678 http://dx.doi.org/10.1155/2021/6620585 |
work_keys_str_mv | AT gourgoulianiskonstantinos prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT ruggierialessandro prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT delvecchioalessandra prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT calistifabrizio prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT comandinialessandro prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT espositogiovanna prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT diloretogiorgio prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy AT tzanakisnikolaos prulifloxacineffectivenessinmoderatetosevereacuteexacerbationsofchronicbronchitisanoninterventionalmulticentreprospectivestudyinreallifeclinicalpracticetheaiolosstudy |